Cyclopol on Electrophysiological Monitoring During Spine Surgery: a Randomized Controlled, Noninferiority Study
Launched by BEIJING TIANTAN HOSPITAL · Nov 8, 2022
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method of anesthesia called total intravenous anesthesia based on cyclopol, and how it affects a test called Flash Visual Evoked Potential (FVEP) during spinal surgery. The FVEP test helps doctors monitor a patient's visual function while they are under anesthesia. This is important because changes in visual function during surgery can lead to long-term problems after the procedure. The study is comparing the effects of cyclopol to a commonly used anesthetic called propofol to see if cyclopol can better protect patients’ vision during surgery.
To participate in this trial, you need to be between 18 and 65 years old and scheduled for elective spinal surgery that requires monitoring of your visual function. You should also be generally healthy, without significant issues like severe liver or kidney disease, uncontrolled high blood pressure, or a history of drug abuse. If you choose to join the study, you can expect to receive either the cyclopol-based anesthesia or propofol, and your visual function will be monitored closely throughout your surgery. This trial is currently recruiting participants, and your involvement could help improve the safety of anesthesia used in spinal surgery for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients undergoing elective spinal surgery under general anesthesia;
- • 2. Intraoperative electrophysiological monitoring is required;
- • 3. 18-65 years old;
- • 4. ASA I-III;
- • 5. Sign the informed consent.
- Exclusion Criteria:
- • 1. Patients with visual impairment;
- • 2. Patients with severe liver or kidney disease;
- • 3. Uncontrolled hypertension, diabetes, severe arrhythmia or unstable angina pectoris;
- • 4. Have mental illness or unable to communicate;
- • 5. BMI≥30kg/㎡;
- • 6. Abuse of analgesics and drug abuse history;
- • 7. Muscle weakness, motor dysfunction or neuromuscular junction disease before operation;
- • 8. Preoperative somatosensory dysfunction;
- • 9. Retain trachea catheter after operation;
- • 10. Narcotic drugs and silicone allergy;
- • 11. Visual evoked potential monitoring was rejected.
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Ruquan Han
Principal Investigator
Beijing Tiantan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials